Annalisa Arcari
YOU?
Author Swipe
View article: Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase <scp>II</scp> multicentre <scp>FIL</scp> Copa‐<scp>BR</scp> trial from Fondazione Italiana Linfomi (<scp>FIL</scp>)
Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase <span>II</span> multicentre <span>FIL</span> Copa‐<span>BR</span> trial from Fondazione Italiana Linfomi (<span>FIL</span>) Open
Summary Treatment options for relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR)‐T‐cell therapy remain limited. The PI3K inhibit…
View article: 277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI
277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI Open
View article: Retrospective Analysis of R-COMP Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Assessing the Impact of Sample Selection Bias
Retrospective Analysis of R-COMP Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Assessing the Impact of Sample Selection Bias Open
Background: Retrospective studies are often criticized for their susceptibility to case selection bias compared to prospective studies, which include all patients consecutively and are thus less prone to such limitations. However, the larg…
View article: Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study Open
View article: Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment Open
Chronic Lymphocytic Leukemia (CLL) is the most frequent type of leukemia in Western countries. In recent years, there have been important advances in the knowledge of molecular alterations that underlie the disease’s pathogenesis. Very het…
View article: Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial Open
Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesti…
View article: Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study Open
Treatment of diffuse large B-cell lymphoma (DLBCL) in older patients is challenging, especially for those who are not eligible for anthracycline-containing regimens. Fondazione Italiana Linfomi (FIL) started the FIL_ReRi study, a 2-stage s…
View article: New treatment options in elderly patients with Diffuse Large B-cell Lymphoma
New treatment options in elderly patients with Diffuse Large B-cell Lymphoma Open
Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (>65 years of age) and this population is expected to increase in the following years. A simplified geriatric assessment based on a careful evaluation of the fitness statu…
View article: A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma Open
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially …
View article: COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL
COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL Open
Introduction: In follicular lymphoma (FL), FDG-PET is routinely employed to evaluate response at the end of induction (EoI), while minimal residual disease (MRD) analysis is highly reliable in predicting relapse over the entire disease his…
View article: Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study Open
Introduction: Patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) have poor outcome. Time to first relapse or progression (POD) has been consistently shown to be an independent predictor of survival, with patients experie…
View article: FRONTLINE INTENSIFIED ABVD DEMONSTRATES SUPERIOR EFFICACY THAN PET‐ADAPTED ABVD IN ADVANCED HODGKIN LYMPHOMA: THE FIL‐ROUGE PHASE 3 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI
FRONTLINE INTENSIFIED ABVD DEMONSTRATES SUPERIOR EFFICACY THAN PET‐ADAPTED ABVD IN ADVANCED HODGKIN LYMPHOMA: THE FIL‐ROUGE PHASE 3 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI Open
Introduction: PET-adapted ABVD with deferred intensification is the favored therapy for most patients with advanced Hodgkin Lymphoma (HL), while upfront intensification ('first hit') with escBEACOPP remains an option in the high-risk disea…
View article: Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL Open
The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients with mantle cel…
View article: Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study Open
The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a his…
View article: Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL) Open
Octogenarian patients with diffuse large B-cell lymphoma are managed mainly with palliation, but recent improvement in their overall condition makes potentially curative treatment a possibility. Studies have shown that half of selected oct…
View article: Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy Open
Background T cells engineered to target CD19 antigen on neoplastic B cells represent the most striking example of CAR-T cell therapy. The success rate of this therapy is affected by several limitations: target antigen loss, and/or acquisit…
View article: The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi
The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi Open
The Elderly Prognostic Index (EPI) is based on the integration of a simplified geriatric assessment, hemoglobin levels and International Prognostic Index and has been validated to predict overall survival in older patients with diffuse lar…
View article: IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study
IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study Open
View article: Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse Open
Central nervous system (CNS) relapse of mantle cell lymphoma (MCL) is a rare phenomenon with dismal prognosis, where no standard therapy exists. Since the covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in relapsed/r…
View article: P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.
P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL. Open
Background: Optimal consolidation for young R/R FL in the rituximab age remains uncertain and the benefit of ASCT is not clearly established. Aims: The FIL FLAZ12 trial (NCT01827605) is a prospective, multicenter, randomized, phase 3 trial…
View article: PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)
PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB) Open
Background: Diffuse large B cell lymphoma (DLBCL) is curable in 50-60% of cases with frontline RCHOP. Relapsed/refractory (R/R) DLBCL can be cured with salvage treatments in roughly 40-50% of cases with standard available treatments which …
View article: DLBCL with an associated IgM serum paraprotein (IgMs- DLBCL) has poor prognosis and frequent mutations in MYD88, CD79B and TP53 genes
DLBCL with an associated IgM serum paraprotein (IgMs- DLBCL) has poor prognosis and frequent mutations in MYD88, CD79B and TP53 genes Open
PURPOUSE: to assess the clinicopathologic features of a poorly defined subset of diffuse large b-cell lymphoma, which is characterized by the secretion of an IgM paraprotein (IgMs-DLBCL). EXPERIMENTAL DESIGN: multicentre, retrospective, an…
View article: Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study Open
Follicular lymphoma (FL) is an indolent hematological disease, often responsive to the first line of treatment, but characterized by repeated relapses. The therapeutic algorithm for relapsed/refractory FL patients comprises phosphatidylino…
View article: CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)
CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL) Open
Central nervous system (CNS) involvement is a rare but almost fatal complication of diffuse large B-cell lymphoma (DLBCL). There is no consensus on the optimal CNS risk model and prophylaxis treatment. We conducted in all FIL centers a web…
View article: Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study Open
PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy. METHODS We randomly assigned treatment-naïve, adva…
View article: Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience Open
The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post‐ASCT maintenance …
View article: Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience
Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience Open
Background Elderly classical Hodgkin lymphoma (cHL) (ecHL) is a rare disease with dismal prognosis and no standard treatment. Fitness‐based approaches may help design appropriate treatments. Sarcopenia has been associated with an increased…
View article: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL)
DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL) Open
Introduction: Octogenarians are increasingly attending haematological departments and treatment of aggressive lymphoma is challenging in this category of patients (pts). Comprehensive geriatric assessment (CGA) has proven useful in guiding…
View article: ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY
ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY Open
Introduction: Peripheral T-cell lymphomas (PTCL) are a rare disease with a poor prognosis, even when treated with high dose chemotherapy and stem cell transplantation (HDC + SCT). Romidepsin (Ro), a histone deacetylase inhibitor, showed ac…
View article: SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCE
SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCE Open
Introduction: Classical Hodgkin Lymphoma in the elderly (ecHL) is a rare disease with dismal prognosis and no standard treatment. In elderly lymphoma patients (pts) functional status evaluation helps define different prognostic subgroups a…